WALTHAM, Mass., March 03, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate a panel discussion focused on new approached to treat gastroenterological diseases and a corporate fireside chat at the TD Cowen 43rd Annual Health Care Conference.
Presentation Information
GI/Microbiome Panel Discussion
9:10 AM ET, Monday March 6, 2023
Fireside Chat
11:10 AM ET, Monday, March 6, 2023
A live webcast of the presentations will be available on the Investor section of Morphic’s website at www.morphictx.com. An archived replay will be available on the company’s website following the conference.
About Morphic Therapeutic
Morphic Therapeutic is a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer. Morphic is also advancing its pipeline and discovery activities in collaborations with Janssen using its proprietary MInT technology platform which leverages the Company’s unique understanding of integrin structure and biology. For more information, visit www.morphictx.com.
Contacts
Morphic Therapeutic
Chris Erdman
This email address is being protected from spambots. You need JavaScript enabled to view it.
617.686.1718
| Last Trade: | US$56.99 |
| Daily Volume: | 0 |
| Market Cap: | US$2.860B |
April 25, 2024 February 22, 2024 January 03, 2024 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
